ea0092ps2-18-04 | Treatment 1 | ETA2023
Wirth Lori
, Worden Francis
, Morris John
, Medioni Jacques
, Deschler-Baier Barbara
, Han Yimei
, Kiiskinen Urpo
, Jen Min-Hua
, Barker Scott
, Szymczak Sylwia
, Gilligan Adrienne
Objective: Head-to-head data comparing selpercatinib, a highly selective and potent RE arranged during Transfection (RET) kinase inhibitor with CNS activity, to standard treatment of RET-altered medullary thyroid cancer (MTC; cabozantinib or vandetanib) is currently unavailable. This post-hoc comparative effectiveness analysis of data from the phase 1/2 LIBRETTO-001 trial compared investigator-assessed outcomes among patients with RET</e...